This MedLibrary.org supplementary page on Olopatadine is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Olopatadine
|
|
| Systematic (IUPAC) name | |
| {(11Z)-11-[3-(dimethylamino)propylidene]-6,11- dihydrodibenzob,eoxepin-2-yl}acetic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | S01 R01AC08 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H23NO3 |
| Mol. mass | 337.412 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 3 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status | |
| Routes | Ophthalmic, intranasal, oral |
Olopatadine hydrochloride is an antihistamine and mast cell stabilizer, sold as a prescription eye drop (0.2% solution, trademark Pataday (or Patanol S in some countries), manufactured by Alcon). It is used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine hydrochloride 0.1% is sold as trademark Patanol (or Opatanol in some countries). A nasal spray formulation is sold as trademark Patanase, which was approved by the FDA on April 15, 2008.[1] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.[2]
It should not be used to treat irritation caused by contact lenses. The usual dose for trademark Pataday is 1 drop in each affected eye once a day. The usual dose for trademark Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses.
Its side effects may include headaches (7% of occurrence) burning and stinging (5%), dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste change.
Olopatadine was developed by Kyowa Hakko Kogyo.[3]
References
- ^ Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
- ^ Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK® Tablets 2.5 & ALLELOCK® Tablets 5 (English)". Retrieved on 2008-08-10.
- ^ Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd.. Retrieved on 10 August, 2008.
External links
|
|||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 10 August 2008, at 19:08.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Olopatadine".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.